Branded

SILVER SPRING, Md. — The Food and Drug Administration last week approved Adamis Pharmaceuticals’ Symjepi, a pre-filled dose syringe of epinephrine. The syringe is indicated for emergency treatment of allergic reactions, including anaphylaxis.

WOONSOCKET, R.I. — In an attempt to gauge patients’ attitudes toward the cost of prescription drugs, CVS Health in April conducted a survey of registered voters, whose results the company released Thursday. The survey found that 88% of respondents are somewhat or very concerned about the high cost of prescription drugs.

PHOENIX — The Healthcare Distribution Alliance’s nonprofit HAD Research Foundation has awarded Upsher-Smith Laboratories’ VP partner relations Mike McBride its 2017 Nexus Award for Lifetime Achievement.

The award — which was given by the foundation, alongside Genentech and Mylan at the HDA’s annual Business and Leadership Conference — recognizes character and professional accomplishments, as well as leadership in HDA, the industry and the community.

WASHINGTON — The National Association of Chain Drug Stores and the American Pharmacists Association this week urged the Trump administration to steer clear of legislation that would clear the way for the importation of prescription drugs from other countries.

The two penned a letter calling on Pres. Trump and administration officials to “refrain from endorsing pending legislative proposals that would allow for broad personal and commercial importation of non-[Food and Drug Administration (FDA)] approved prescription drugs.”

DANBURRY, Conn. and RESEARCH TRIANGLE PARK, N.C. — The latest report from the QunitilesIMS Institute is highlighting strides made in oncology therapies and the robust pipeline of forthcoming treatments.

The report, Global Oncology Trends 2017: Advances, Complexity and Cost, notes that 68 novel therapies have been approved globally across 22 cancer indications since 2011, providing more access and better outcomes for patients, particularly those with metastatic cancers.

UMBAI, BALTIMORE and BOISE, Idaho — Albertsons and Lupin Pharmaceuticals announced a new partnership that would bring Lupin’s InspiraChamber to all of Albertsons’ banner pharmacies as the retailer’s preferred inhaled aerosol therapy chamber.

The holding chamber will be available at the more than 1,7000 pharmacies in the 35 states that Albertsons operates, the companies said.

ATLANTA — A new study in the journal Clinical Infectious Diseases found that flu vaccination reduced deaths, intensive care unit admissions, ICU length of stay and overall duration of hospitalization among hospitalized flu patients. This study is an important first step in better understanding whether flu vaccines can reduce severe flu outcomes even if they fail to protect against infection.

PRINCETON, N.J. — Bristol-Myers Squibb announced Wednesday that the U.S. Food and Drug Administration accepted a supplemental Biologics License Application that seeks to extend the use of Opdivo (nivolumab) to patients with hepatocellular carcinoma after prior sorafenib therapy. The FDA granted the application priority review and previously granted Opdivo orphan-drug designation for the treatment of HCC.

The FDA action date on the application Sept. 24.